Vanderbilt Eye Institute Archives
Feb. 4, 2016—Tonia Rex, Ph.D., and colleagues at the Vanderbilt Eye Institute are working to uncover how best to treat ocular trauma, the fourth leading cause of blindness worldwide.
Jan. 7, 2016—Sight is one of the most critical elements of a normal, happy life. When a child’s eyesight is threatened, his or her future stands to be permanently altered — and parents try to find the best treatment available.
Daniels receives research grant from Knights Templar Eye Foundation to study retinoblastoma treatment
Jun. 25, 2015—Vanderbilt investigator Anthony Daniels has received a grant from the Knights Templar Eye Foundation to develop new, safe and effective treatments for retinoblastoma, the most common ocular cancer in children.
Jun. 25, 2015—The Vanderbilt Eye Institute recently received a grant for $115,000 from Research to Prevent Blindness, placing the total award amount for unrestricted grants from the organization at $860,000.
Beware the eyes of March: Vanderbilt ophthalmologist offers tips for preventing and treating dry eyes during windy weather
Mar. 23, 2015—For the past few months, much of the nation has donned hats, boots, scarves and gloves as they face brutally cold and icy conditions of winter. As temperatures rise, making outdoor activities more enticing, Vanderbilt ophthalmologists suggest not to be in such a hurry to stop protecting yourself from the elements. Why? March is known...
Feb. 12, 2015—John Penn, Ph.D., Phyllis G and William B. Snyder Endowed Professor of Ophthalmology and Visual Sciences, has been named president-elect of the International Society for Eye Research (ISER).
Oct. 16, 2014—It’s been 20 years since Project PAVE, a Tennessee program providing low-vision evaluations for children, was launched.
Oct. 9, 2014—Conventional therapy for patients diagnosed with retinoblastoma, the most common ocular cancer in children, includes systemic chemotherapy, external beam radiation and/or surgical removal of the eye. Doctors at Vanderbilt University Medical Center are on track to radically change the way the disease is treated using an emerging therapeutic approach called intra-arterial chemotherapy, or IA chemo.